Table 2 Incidence of heart failure hospitalization according to exposure of daily dose from the study cohorts.

From: Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study

Variable

N

Event

PYs

Rate

Crude HR (95% CI)

Adjusted HR (95% CI)

Sitagliptin users

 No

3480

309

4098

754

ref

ref

 Yes

870

103

911

1130

1.49(1.2–1.87)

1.52(1.21–1.90)

DDD

 None

3480

309

4098

754

ref

ref

 Low

674

74

740

1000

1.32(1.02–1.7)

1.35(1.04–1.74)

 Intermediate

149

22

133

1653

2.18(1.42–3.37)

2.16(1.40–3.35)

 High

47

7

38

1848

2.44(1.15–5.17)

2.57(1.21–5.47)

p for trend

    

<0.0001

<0.0001

  1. The model was adjusted for age, sex, type of dialysis, DM duration, Taiwan comorbidity index, ACEI, ARB, α-blocker, CCB, diuretics, statins, aspirin, severe hypoglycemia, SU, glinide, and insulin.
  2. DDD, defined daily dose; PYs, person-years; CI, confidence interval; HR, hazard ratio.
  3. Low dose exposure, <180 DDD per year; intermediate dose exposure, 180–359 DDD per year; high dose exposure, ≥360 DDD per year.
Back to article page